Free tool
Drug Trial Radar: Oncology
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
20
Active, not recruiting, industry sponsors, Oncology, Phase 4 (post-approval)
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed335
20 trials
Showing 1 to 20, recently updated first.
- Pediatric Long-Term Follow-up and Rollover StudyActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT03975829 · 163 participants · Start Nov 4, 2019 · Primary completion Nov 24, 2026
Drug: dabrafenib; trametinib · For: Diffuse Astrocytoma; Anaplastic Astrocytoma; Astrocytoma and 20 more
Sites: Phoenix, Arizona; Washington D.C., District of Columbia; Miami, Florida · 54 sites in all
- Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia GravisActive, not recruiting
NCT07246564 · 40 participants · Start Dec 1, 2025 · Primary completion Jun 3, 2027
Drug: Rozanolixizumab · For: Myasthenia Gravis
Sites: Beijing, China; Changchun, China; Changsha, China · 12 sites in all
- A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple MyelomaActive, not recruiting
Johnson & Johnson Private LimitedJohnson & Johnson (Janssen) (JNJ)
NCT07030517 · 75 participants · Start May 22, 2025 · Primary completion Feb 12, 2027
Drug: Teclistamab · For: Multiple Myeloma
Sites: Bangalore, India; Bengaluru, India; Chandigarh, India · 12 sites in all
- RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)Pivotal-lookingActive, not recruiting
BayerBayer (BAYRY)
NCT04597125 · 654 participants · Start Nov 9, 2020 · Primary completion Nov 21, 2025
Drug: Radium-223 dichloride (Xofigo, BAY88-8223); ARPI therapy · For: Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Sites: Castle Hill, Australia; Gosford, Australia; Kingswood, Australia · 117 sites in all
- A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid CancerPivotal-lookingActive, not recruiting
ExelixisIndustry
NCT01896479 · 247 participants · Start Feb 25, 2015 · Primary completion Jul 15, 2020
Drug: Cabozantinib (XL184) 140 mg; Cabozantinib (XL184) 60 mg and 2 more · For: Medullary Thyroid Cancer
Sites: St Leonards, Australia; Herston, Australia; Kurralta Park, Australia · 49 sites in all
- CINC424A2X01B Rollover ProtocolActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT02386800 · 279 participants · Start Mar 5, 2015 · Primary completion Apr 5, 2032
Drug: ruxolitinib; panobinostat · For: Primary Myelofibrosis; Polycythemia Vera; Graft Versus Host Disease and 2 more
Sites: Darlinghurst, Australia; Herston, Australia; Wooloongabba, Australia · 97 sites in all
- Roll-over Study to Allow Continued Access to RibociclibActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT05161195 · 134 participants · Start Jul 7, 2022 · Primary completion Jun 28, 2030
Drug: Ribociclib; Letrozole and 4 more · For: Metastatic Breast Cancer
Sites: Chandler, Arizona; Fayetteville, Arkansas; Beverly Hills, California · 73 sites in all
- Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving TopotecanPivotal-lookingActive, not recruiting
Pharmacosmos A/SIndustry
NCT05874401 · 302 participants (planned) · Start Oct 13, 2023 · Primary completion Feb 5, 2028
Drug: Trilaciclib; Placebo and 1 more · For: Extensive-stage Small-cell Lung Cancer
Sites: Seville, Spain
- Lorlatinib Continuation StudyActive, not recruiting
PfizerPfizer (PFE)
NCT05144997 · 76 participants · Start Dec 28, 2021 · Primary completion Oct 25, 2029
Drug: Lorlatinib · For: Non-Small-Cell Lung Cancer; NSCLC
Sites: Irvine, California; Hefei, China; Beijing, China · 27 sites in all
- Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored StudyActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT02584933 · 233 participants · Start Dec 11, 2015 · Primary completion Jun 9, 2027
Drug: ceritinib · For: ALK Positive Malignancies
Sites: Fayetteville, Arkansas; Loma Linda, California; Aurora, Colorado · 71 sites in all
- Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian PatientsActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT06429761 · 100 participants · Start Jan 2, 2025 · Primary completion Oct 31, 2026
Drug: Trastuzumab deruxtecan · For: BREAST CANCER
Sites: Bangalore, India; Delhi, India; Kochi, India · 7 sites in all
- Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral SolutionActive, not recruiting
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT05044819 · 154 participants · Start Jul 7, 2021 · Primary completion Aug 1, 2027
Drug: Cannabidiol · For: Lennox Gastaut Syndrome; Dravet Syndrome; Tuberous Sclerosis Complex
Sites: Little Rock, Arkansas; Downey, California; Long Beach, California · 26 sites in all
- A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström MacroglobulinemiaActive, not recruiting
BeiGeneBeOne Medicines (BeiGene) (ONC)
NCT07169331 · 16 participants · Start Oct 17, 2025 · Primary completion Oct 31, 2028
Drug: Zanubrutinib · For: Waldenström's Macroglobulinemia
Sites: Beijing, China; Guangzhou, China; Baoding, China · 6 sites in all
- A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemophilia A on Efanesoctocog Alfa ProphylaxisActive, not recruiting
Swedish Orphan BiovitrumIndustry
NCT06752850 · 37 participants · Start Dec 19, 2024 · Primary completion Nov 17, 2026
Drug: Efanesoctocog alfa · For: Haemophilia A (Moderate or Severe); Hemophilia, Classic; Haemophilia and 3 more
Sites: Milan, Italy; Naples, Italy; Rozzano, Italy · 10 sites in all
AstraZenecaAstraZeneca (AZN)
NCT05457257 · 43 participants · Start Jul 29, 2022 · Primary completion Oct 22, 2024
Drug: olaparib; enzalutamide and 2 more · For: Metastatic Castration-resistant Prostate Cancer
Sites: Beijing, China; Bengbu, China; Changsha, China · 35 sites in all
- Crizotinib Continuation Clinical StudyActive, not recruiting
PfizerPfizer (PFE)
NCT05160922 · 27 participants · Start Dec 27, 2021 · Primary completion Mar 21, 2028
Drug: crizotinib · For: NSCLC; ALCL; IMT
Sites: Beijing, China; Fuzhou, China; Guangzhou, China · 13 sites in all
- Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.Active, not recruiting
Pharmacyclics Switzerland GmbHAbbVie (ABBV)
NCT03229200 · 297 participants · Start May 22, 2017 · Primary completion May 10, 2027
Drug: Ibrutinib · For: Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, B-cell and 2 more
Sites: Burbank, California; Duarte, California; La Jolla, California · 98 sites in all
- Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the BoneActive, not recruiting
AmgenAmgen (AMGN)
NCT04586660 · 36 participants · Start Aug 17, 2023 · Primary completion Mar 7, 2028
Drug: XGEVA® · For: Giant Cell Tumor of Bone
Sites: Beijing, China; Fuzhou, China; Guangzhou, China · 10 sites in all
AbbVieAbbVie (ABBV)
NCT05144243 · 44 participants · Start Jan 6, 2022 · Primary completion Mar 2026
Drug: Venetoclax; Azacitidine · For: Acute Myeloid Leukemia (AML)
Sites: Beijing, China; Guangzhou, China; Shenzhen, China · 18 sites in all
- A Study of Tirbanibulin Ointment and Diclofenac Sodium Gel for the Treatment of Adult Participants With Actinic Keratosis on the Face or ScalpPivotal-lookingActive, not recruiting
Almirall, S.A.Industry
NCT05387525 · 447 participants · Start Oct 24, 2022 · Primary completion Jul 2027
Drug: Tirbanibulin (Klisyri®) 10 mg/g ointment; Diclofenac Sodium 3% Gel · For: Keratosis, Actinic
Sites: Lille, France; Marseille, France; Nice, France · 49 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.